news
Novel Alzheimer’s vaccine shows promise in murine models
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
List view / Grid view
Immunology
news
Novel siRNA therapy improves psoriasis in mice
Topical delivery of a small interfering RNA (siRNA) using an ionic liquid complex significantly reduced levels of inflammatory cytokines and symptoms of psoriasis.
news
Researchers uncover drivers of memory B cell formation
The team demonstrated that expression of Bach2 protein and reduced mTORC1 activity is necessary for germinal B cells to become memory B cells.
video
Video: Gain deeper insights into cellular 3D structures with water immersion objectives
Water immersion objectives are essential for capturing more data at greater depths in 3D structures, such as spheroids and thick tissues.
news
COVID-19 vaccines should not be affected by SARS-CoV-2 mutations, researchers say
A common SARS-CoV-2 mutation known as D614G should not impact on the efficacy of COVID-19 vaccines, a study has shown.
news
SARS-CoV-2-targeting antibodies persist for at least three months in COVID-19 patients
Two separate studies show that IgG serotype antibodies targeting the SARS-CoV-2 spike protein are still detectable in patient’s blood and saliva after 90 days.
news
Team identifies T-cell epitopes to inform COVID-19 vaccine development
Researchers studied 180 convalescent COVID-19 patients to reveal T-cell epitopes that they say can be targeted by a vaccine.
news
Using CRISPR to develop a cutaneous leishmaniasis vaccine
Researchers used CRISPR gene-editing to develop a vaccine able to protect against the spread of the Leishmania major parasite which causes cutaneous leishmaniasis.
news
Could a sphingosine nasal spray prevent COVID-19?
According to a study, the lipid sphingosine can inhibit SARS-CoV-2 infection and could potentially be delivered in a nasal spray to prevent COVID-19 infections.
news
Study shows MAIT cells highly engaged in the immunological response to COVID-19
New research has shown that MAIT cells are strongly activated in people with moderate to severe COVID-19 disease.
video
Video: ImageXpress Pico Virtual Tour
Explore this virtual tour of the ImageXpress Pico Automated Cell Imaging System from Molecular Devices, including hardware and software.
news
Why do some patients develop COVID-19 pneumonia?
Scientists reveal that some patients who develop severe COVID-19 symptoms mount ineffective immune responses due to a lack of type I interferons, either through genetic mutation or inactivation by auto-reactive antibodies.
video
Video: ImageXpress Micro Confocal Virtual Tour
Explore this virtual tour of the ImageXpress Micro Confocal High-Content Imaging System from Molecular Devices, including hardware and software.
news
Team reveals why children’s immune response to COVID-19 is better than adults’
Researchers have identified two molecules that explain why children experience COVID-19 differently to adults.
webinar
Next generation strategies for cancer immunotherapy
24 September 2020 | By PerkinElmer
During this on-demand webinar, two leading researchers will discuss their innovative approaches to developing novel opportunities for immunotherapy treatments.